Overview
- GSK shares have risen about 38% over the past year, roughly matching the gain since Jim Cramer backed the stock in March 2025.
- The stock climbed 7.3% after its fourth-quarter report beat forecasts with £8.6 billion in revenue and 25.5 pence in earnings per share.
- Earlier, GSK raised its 2025 revenue growth outlook to 6% to 7% from 3% to 5% after third-quarter results topped estimates with £8.6 billion in revenue and 55 pence EPS.
- The company moved into weight loss by agreeing to acquire 35Pharma, adding the HS235 candidate that targets fat loss while aiming to preserve muscle mass.
- Cramer praised CEO Dame Emma Walmsley, cited the stock’s low price-to-earnings ratio and 4% dividend yield, and told viewers to buy the shares and hold them.